Insilico Medicine– tag –
-
Insilico Medicine’s AI-Designed Drug Rentosertib Shows Early Signs of Biological Age Reversal, Enters Phase III for Idiopathic Pulmonary Fibrosis
Inc.com USA Overview Insilico Medicine's AI-generated small molecule, rentosertib, has demonstrated early signs of reducing six protein-based biological age markers by an average of 10.3% in a 12-week clinical trial. This breakthrough ma... -
AI and Advanced Pharma Tech Converge: Insilico’s INS018_055 Achieves Clinical Success
MDPI Switzerland Overview Artificial intelligence and machine learning are revolutionizing pharmaceutical R&D by integrating with advanced technologies like pharmacogenomics and organ-on-a-chip systems. AI-designed drugs, such as Ins... -
AI Accelerates Drug Discovery: AlphaFold, Generative Models Drive R&D Efficiency & Clinical Pipeline Growth
Markets Insider USA Overview AI has dramatically accelerated drug discovery over the past five years through advancements in protein structure prediction, generative chemistry, and phenotypic screening. Tools like DeepMind's AlphaFold ha... -
AI-Discovered Drugs Advance: Insilico Medicine’s Rentosertib Enters Phase III, But Fully AI-Designed Drugs Await Approval (As of 2026)
Life Science Daily News Global Overview As of 2026, AI-generated pharmaceuticals are rapidly advancing through clinical development, with Insilico Medicine's Rentosertib reaching Phase III trials—a significant milestone for AI drug disco... -
Eli Lilly Builds Pharmaceutical Industry’s Largest AI Factory with NVIDIA Blackwell DGX SuperPODs, Secures Multi-Billion Dollar Deals with Insilico Medicine and Isomorphic Labs
GlobeNewswire USA Overview In Q2 2026, as AI technology investment accelerated across industries, Eli Lilly announced the construction of the pharmaceutical sector's largest AI factory, powered by NVIDIA Blackwell-based DGX SuperPODs. Co... -
Generate Biomedicines’ AI-Designed Antibody GB-0895 Advances to Global Phase 3 for Severe Asthma; Insilico Medicine’s IPF Drug also Reaches Phase 3
Stock Titan USA Overview Generate Biomedicines announced its AI-designed anti-TSLP monoclonal antibody, GB-0895, has advanced to global Phase 3 clinical trials for severe asthma, highlighted in its Q2 2026 financial results. Novartis has... -
Insilico Medicine and Saudi Aramco Unveil sorbaMOF DB to Accelerate AI-Driven MOF Discovery for DAC Technologies
Unibest Industrial Co., Ltd. International Overview Insilico Medicine, in collaboration with Saudi Aramco, has launched 'sorbaMOF DB,' a validated materials database with an interpretable AI framework designed to accelerate the discovery... -
AI Compresses Drug Discovery Timelines from Years to Months, Insilico Medicine’s IPF Drug Advances to Phase 2 in 18 Months
MarketScale USA Overview Generative AI is dramatically shortening drug discovery timelines, reducing development from years to months. Insilico Medicine's platform successfully advanced a candidate compound for idiopathic pulmonary fibro... -
Isomorphic Labs: AI-Designed Drugs Head to Human Trials, Reshaping Pharma’s Future
Wired USA Overview Isomorphic Labs, a Google DeepMind spin-off, is on the verge of commencing human clinical trials for drugs entirely designed by artificial intelligence. Leveraging its foundational AlphaFold system, the company aims to... -
FDA Grants Fast Track and Priority Review to Multiple Cancer Drugs in July 2026: Insilico Medicine’s ISM6331 Receives Designation for Mesothelioma
Pharmacy Times USA Overview In July 2026, the FDA granted Fast Track Designation and Priority Review to several oncology therapeutics, targeting colorectal cancer, anal cancer, malignant pleural mesothelioma, and large B-cell lymphoma. N...
